drugset
drugset / Trial / NCT05363839

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

NCT05363839 ↗

Phase 1 Terminated 8 enrolled Syneos Health Otsuka Pharmaceutical Development & Commercialization, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized single ascending dose placebo controlled treatment of ACH-000029 administered orally via capsule in healthy volunteers.

Timeline

Start
2022-05-06
Primary completion
2022-11-02
Completion
2022-11-02

Outcome

Outcome not reported

Stopped: “Based on the unblinded clinical data, the trial was terminated.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ACH-000029 Unknown 10 mg Oral
Subject ACH-000029 Unknown 30 mg Oral
Subject ACH-000029 Unknown 60 mg Oral

Indications

No indication recorded.